Mukadder SERTER, Serir AKTOĞU, Onur Fevzi ERER, Çiğdem YENİSEY

Plevral effüzyonların ayrımlanmasında CA 125, CA 19,9 ve CA 15,3'ün kullanımı

Amaç: Günümüzde tümör belirleyiciler olarak tanımlanan ve karbohidrat antijenleri olan CA 125, CA 19,9 ve CA 15,3'ün tek başlarına ve birlikte kullanıldığında plevral effüzyonu olan hastalarda teşhisteki yararlılığının değerlendirilmesi. Gereç ve yöntem: Ocak-Eylül 2000 tarihleri arasında Yenişehir Göğüs Hastalıkları Hastanesi 9B ve 8B servislerine başvuran ve plevral effüzyon tanısı alan 68 olgu (26 malign ve 42 benign) çalışmaya dahil edilmiştir. Tümör belirleyiciler IMMULITE I hormon otoanalizöründe kemiluminesans enzim immunometrik yöntem ile BIODPC ticari kitleri yoluyla saptanmıştır. Bulgular: Bütün gruplarda plevral CA 125 düzeyleri, aynı gruplarda serumda elde edilen değerlerden yüksek bulunmuştur. Malign plörezide saptanan ortalama plevra CA 125 ve CA 15,3 değerleri, tüberküloz plörezide saptanan plevra CA 125 ve CA 15,3 düzeylerinden yüksektir. Sonuç: Bu sonuçlar çeşitli tümör belirleyicilerin hem plevra ve hem de serumda ölçülmesinin malign ve benign orijinlerin ayrımlanmasında yararlı olabileceğini göstermiştir.

Anahtar Kelimeler:

Antijenler, ayrımlanma, Plevral efüzyon, Tüberküloz, Tümör belirteci, biyolojik, CA-125 antijen, CA-19-9 antijen, CA-15-3 antijen

CA 125, CA 19,9 and CA 15,3 in differentiation of pleural effusions

Objective: To evaluate the individual and combined diagnostic utility of tumor markers CA 125, CA 19.9 and CA 15.3 in patients with pleural effusions. Material and method: Between January-September 2000 a total of 68 patients (26 malignant and 42 benign) applied to the Yenişehir Chest Hospital at the clinics 9B and 8B were diagnosed suffering from pleural effusion. Tumor markers were determined via chemiluminescent enzyme immunometric assay using BIODPC commercial kits in IMMULITE I hormone analyzer. Results: Pleural CA 125 was found higher in all groups in comparison with their serum value. The mean level of pleural CA 125 and CA 15.3 in malign pleurisy was significantly higher than that in tuberculous pleurisy. Conclusions: These results showed that measurement of various tumor markers in both pleura and serum is useful achieving the differential diagnosis of malignant and benign origin.

Keywords:

Antigens, Differentiation, Pleural Effusion, Tuberculosis, Tumor Markers, Biological, CA-125 Antigen, CA-19-9 Antigen, CA-15-3 Antigen,

PDF

___

1. O’Brien TJ, Raymond ML, Bannon GA, et al. New monoclonal antibodies identify the glycoprotein carrying the CA125 epitope. Am J Obst Gynecol 1991; 156: 1857-1864.
2. Jacobs I, Bast RC, Jr. The CA125 tumour-associated antigen: a review of the literature. Hum Rep 1989;4:1-12.
3. Steinberg W. The clinical utility of the CA 125 tumorassociated antigen. Am J Gastroenterology 1990; 85: 350-355.
4. Yew WW, Chan CY, Kwan SY, Cheung SW, French GL. Diagnosis of tuberculosis pleural effusion by the detection of tuberculostearic acid in pleural aspirates. Chest 1991; 100:1261-1263.
5. Tian F, Appert HE, Myles J, Howard JM. Prognostic value of serum CA 19.9 levels in pancreatic adenocarcinoma. Ann Surg 1992; 215: 350-355.
6. Colomer R, Ruibal A, Genolla J, et al. Circulating CA 15.3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res Treat 1989; 13: 123-133.
7. Colomer R, Ruibal A, Salvador L. Circulating tumor marker levels in advanced breast carcinoma correlate with extent of metastatic disease. Cancer 1989; 64: 1674-1681.
8. Mezger J, Permanetter W, Gerbes AL, Wilmanns W, Lamerz R. Tumour-associated antigens in diagnosis of serous effusions. J Clin Pathol 1988; 41:633-643.
9. Tamura S, Nishigaki T, Moriwaki Y, et al. Tumor markers in pleural effusion diagnosis. Cancer 1988; 61: 298-302.
10. Tarn AC, Lapworth R. Biochemical analysis of pleural fluid: What should we measure? Ann of Clin Biochem 2001; 38: 311-322.
11. Hausheer FH, Yarbro JW. Diagnosis and treatment of malignant pleural effusion. Semin Oncol 1985;12:54-57.
12. De Wit D, Maatens G, Steyn L. A comparative study of the polymerase chain reaction and conventional procedures for the diagnosis of tuberculous pleural effusion. Tuberc Lung Dis 1992; 73:262-267.
13. Villegas MV, Labrada LA, Saravia NG. Evaluation of polymerase chain reaction, adenosine deaminase, and interferon in pleural fluid for the differential diagnosis of pleural tuberculosis. Chest 2000; 118: 1355-1364.
14. Light RW, Macgregor MI, Luchsinger PC, et al. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med 1972; 77: 507-513.
15. Aoe K, Hiraki A, Murakami T, et al. Diagnostic significance of interferon-gamma in tuberculosis pleural effusions. Chest 2003; 123:740-744.
16. Escudero-Bueno C, Garcia-Clemente M, Cuesta-Castro B.Molinos Martin L, Rodriguez R, Gonzalez Panizo A, Martinez Glez-Rio J. Cytologic and bacteriologic analyzes of fluid and pleural biopsy with Cope’s needle. Arch Intern Med 1990; 150: 1190-1194.
17. Barbas CS, Cukier A, de Varvalho CR, Barbas Filho JV, Light RW. The relationship between pleural fluid findings and development of pleural thickening in patients with pleural tuberculosis. Chest 1991; 100: 1264-1267.
18. San Jose ME, Alvarez D, Valdes L, Sarandeses, Valee JM, Penela P. Utility of tumour markers in the diagnosis of neoplastic pleural effusion. Clin Chim Acta 1997; 265:193-205.
19. Ichiki H, Shishido M, Nishitani K, et al. Evaluation of CEA, SLX and CA 125 in active pulmonary tuberculous. Nihon Kyobu Shikkan Gakkai Zasshi 1993; 31: 1522-1527.
20. Nakanishi Y, Hiura K, Katoh O, et al. Clinical significance of serum CA 125 in patients with tuberculous pleurisy. Kekkaku 1991;66:525-530.
21. Mitsutake Y, Hiromatsu Y, Saisho M, et al. Immunological assay of the CA 125 value in pleural effusion in various types of pleuritis-its application as a differential diagnostic parameter of tuberculous or carcinomatous pleuritis. Gan No Rinsho 1986;32:453-457.
22. Türk HM, Pekdemir H, Büyükberber S, et al. Serum CA 125 levels in patients with chronic heart failure and accompanying pleural fluid. Tumour Biol 2003; 24: 172-175.
23. D’Aloia A, Fraggiano P, Aurigemma G, et al. Serum levels of cerbohydrate antigen 125 in patients with chronic heart failure. J Am College Cardiology 2003; 41: 1805-1811.
24. Niwa Y, Shimokata K. Diagnostic significance of cancer antigen 125, pancreatic oncofetal antigen and carcinoembryonic antigen in malignant and tuberculous pleural effusions. Jpn J Clin Oncol 1986;16:3-8.
25. Niwa Y, Kishimoto H, Shimokata K. Carcinomatous and tuberculous pleural effusions: comparison of tumor markers. Chest 1985; 87:351-355.
26. Villena V, Lopez-Encuentra A, Echave-Sustaeta J, Martin-Escribano P, Ortuno-de-Solo B, Estenoz- Alfaro J. Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15.3, and CA 19.9 assay in pleural fluid. A study of 207 patients. Cancer 1996;78:736-740.
27. Romero S, Fernandez C, Arriero JM, et al. CEA, CA 15.3 and CYFRA 21-1 in serum and pleural fluid of patients with pleural effusions. Eur Respir J 1996;9:17-23.
28. Kuralay F, Tokgöz Z, Çömlekci A. Diagnostic usefulness of tumour marker levels in pleural effusions of malignant and benign origin. Clin Chim Acta 2000; 300: 43-55.
29. Yenisey C, Yenice S, Güner G, Güner S. Quantitation of MCA, CA 19.9, CA 125 and TSA levels in lung cancer. Biochemical Society Transactions 1995; 23: 530.
30. Yenisey C, Yenice S, Güner G, Güner S. Evaluation of tumor-associated antigens and total sialic acid levels in effusions of malignant and benign origin. Biochemical Society Transactions 1996; 24: 301.
31. Hayashibe A, Kodama T, Nishiwaki Y, Kudou H, Inoue Y, Nukariya N. Clinical evaluation of serum carbohydrate antigen CA 19.9 in carcinoma of the lung-a comparison with carcinoembriyonic antigen. Gan To Kagaku Ryoho 1987; 14: 711-715.
32. Alata F, Alata Ö, Metin M, Çolak Ö, Harmancı E, Demir S. Diagnostic value of CEA, CA 15.3, CA 19.9, CYFRA 21.1, TSA and NSE assay in pleural effusions. Lung Cancer 2001; 31: 9-16.